Oppenheimer analyst Esther Rajavelu lowered her price target for GW Pharmaceuticals to $222 following the company's quarterly results, saying Q3 revenues were in line with estimates. Though GW Pharmaceuticals met her Q3 topline expectations, Rajavelu tells investors in a research note that she is lowering Epidiolex revenue estimates for future periods as she anticipates moderating new patient numbers and higher attrition rates. She keeps an Outperform rating on the shares, as she continues to believe Epidiolex use in multiple seizure types is not fully reflected in the stock at current levels.